Detection and management of renal cell carcinoma in the renal allograft

Végsô, Gyula; Toronyi, É.; Deák, Pál Ákos; Doros, Attila; Langer, Róbert

doi:10.1007/s11255-012-0274-1

Cited by 26 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunomodulation and immunosuppression induced to allow viability of the renal allograft can provide a more favorable niche for the malignant cells to emerge and thrive [ 2 , 10 , 20 , 21 ]. In renal transplant patients, allograft malignancies in the immunosuppressed state are often more aggressive [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes

et al. 2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes

et al. 2020

View full text Add to dashboard Cite

“…Annual US surveillance aids in the early detection of allograft and native kidney RCCs (24,62). Whereas radical nephrectomy is the recommended treatment in most native kidney RCCs, percutaneous ablation and nephron-sparing surgery are preferred for tumors in the transplant kidney (64). Thermal ablation, including radiofrequency ablation and cryoablation, has been shown to be a safe and effective therapy in treating de novo renal allograft RCCs, with low morbidity and without modification of the immunosuppressive regimen (65).…”

Section: Rccmentioning

confidence: 99%

Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review

Katabathina¹,

Menias²,

Tammisetti³

et al. 2016

RadioGraphics

View full text Add to dashboard Cite

Life expectancies for solid organ recipients as well as graft survival rates for these patients have improved over the years because of advanced immunosuppressive therapies; however, with chronic use of these drugs, posttransplant malignancy has become one of the leading causes of morbidity for them. The risk of carcinogenesis in transplant recipients is significantly higher than for the general population and cancers tend to manifest at an advanced stage. Posttransplant malignancies are thought to develop by three mechanisms: de novo development, donor-related transmission, and recurrence of a recipient's pretransplant malignancy. Although nonmelanoma skin cancer, Kaposi sarcoma, posttransplant lymphoproliferative disorder, anogenital cancer, and lung cancer are malignancies that are thought to arise de novo, malignant melanoma and cancers that arise in the renal allograft are frequently donor related. Hepatocellular carcinomas and cholangiocarcinomas have a greater tendency to recur in liver transplant recipients. An altered or deranged immune system caused by chronic immunosuppression is considered to be one of the major contributing factors to carcinogenesis. The proposed pathogenic mechanisms for oncogenesis include impaired immunosurveillance of neoplastic cells, weakened immune activity against oncogenic viruses, and direct carcinogenic effects of immunosuppressive agents. Imaging plays an important role in screening, follow-up, and long-term surveillance in patients with malignancies because key imaging features can guide in their timely diagnosis. However, some benign entities such as transplant-related renal fibrosis, biliary necrosis, and infectious nodules in the lungs mimic malignancies and require pathologic confirmation. Management strategies that can improve malignancy-related morbidity and mortality in transplant recipients include prevention of risk factors, appropriate modulation of immunosuppressive agents, prophylaxis against infection-related malignancies, and use of intensive targeted screening programs. (©)RSNA, 2016.

show abstract

“…It is more likely to occur in a native kidney of a transplant recipient than in the transplanted kidney. [1][2][3][4] The first case of a de novo tumor arising in a transplanted kidney was reported in 1988. 5 The incidence was reported to be 0.19% to 0.5%.…”

Section: Figurementioning

confidence: 99%

“…5 The incidence was reported to be 0.19% to 0.5%. [2][3][4]6,7 The mean time lapse between kidney transplantation and de novo RCC in the allograft varied between 3 and 17 years. [7][8][9] There is a better prognosis if RCC is detected early by screening.…”

Section: Figurementioning

confidence: 99%

Renal Cell Carcinoma Arising From Renal Allograft Detected by 18F-FDG PET-CT

Guo

Wang²

2016

Clinical Nuclear Medicine

View full text Add to dashboard Cite

Renal cell carcinoma arising from renal allograft is a rare condition. A 56-year-old man with a history of 3 renal transplantation due to renal failure presented poor appetite and weight loss for 3 months. Possibility of tumor of unknown origin was suspected. For this reason, an FDG PET/CT was performed, and the images showed a hypermetabolic focus in the lower pole of the left renal transplant, suggestive of a malignant lesion. Subsequent pathological examination following allograft nephrectomy confirmed grade 4 renal cell carcinoma.

show abstract

Detection and management of renal cell carcinoma in the renal allograft

Abstract: According to our observation, we can state that RCC of the kidney allograft diagnosed at an early stage can be successfully treated with RFA instead of graft removal. A longer follow-up is needed to assess the effectivity of the RFA treatment in these cases.

Cited by 26 publications

References 19 publications

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes

Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review

Renal Cell Carcinoma Arising From Renal Allograft Detected by 18F-FDG PET-CT

Contact Info

Product

Resources

About